# Oxytocin for Hypermobile Ehlers-Danlos Syndrome

> **NCT05405257** · PHASE1,PHASE2 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 2 (actual)

## Conditions studied

- Hypermobile Ehlers-Danlos Syndrome
- Pain Assessment

## Interventions

- **DRUG:** Oxytocin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05405257
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-13
- **Primary completion:** 2025-03-11
- **Final completion:** 2025-03-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study team has decided to close the trial (NCT05405257) due problems with patient recruitment and enrollment efforts. To date, only one patient completed both arms.
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405257, "Oxytocin for Hypermobile Ehlers-Danlos Syndrome". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05405257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*